10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 1,923,557 | $346,240,270 | +26% | 0.16% |
| 2. | Point72 Asset Management Steve Cohen | 809,617 | $148,427,085 | -72% | 0.19% |
| 3. | Alyeska Investment Group Anand Parekh | 805,050 | $147,589,817 | -22% | 0.42% |
| 4. | Balyasny Asset Management Dmitry Balyasny | 650,046 | $119,172,933 | +7% | 0.15% |
| 5. | Patient Capital Management Samantha Mclemore | 379,741 | $69,618,001 | -35% | 2.55% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $195.04 | 3 | $585.11 | 19,611 | 2026-02-12 | Filing | |
| $122.72 | 1,235 | $151,559.20 | 27,842 | 2025-05-02 | Filing | |
| $222.54 | 455 | $101,255.70 | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | $239,766.00 | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | $748,046.74 | 34,810 | 2020-11-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $199.83 | 2,660 | $531,547.80 | 8,043 | 2026-02-09 | Filing | |
| $179.30 | 748 | $134,116.40 | 6,271 | 2026-02-02 | Filing | |
| $133.55 | 517 | $69,045.35 | 5,772 | 2025-09-02 | Filing | |
| $135.00 | 2,223 | $300,105.00 | 6,330 | 2025-07-08 | Filing | |
| $126.25 | 3,806 | $480,507.50 | 5,427 | 2025-05-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,974,601 | $2,928,623,480 | 0.05% | |
| 2. | 14,757,607 | $2,705,512,094 | 2.13% | |
| 3. | 12,807,541 | $2,348,006,582 | 0.12% | |
| 4. | 9,537,417 | $1,748,494,659 | 0.04% | |
| 5. | 7,167,922 | $1,314,095,140 | 0.05% |
News See All
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript
Operator: Good morning. My name is Cynthia, and I will be your conference operator today.
Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts
Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc.
8 Best Stem Cell Therapy Stocks to Buy
He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly...
Jim Cramer’s 17 Stock Calls: Applied Materials and CoreWeave
In this article, we will look at Jim Cramer’s stock calls on Mad Money recently.
What Makes Biogen (BIIB) an Attractive Long-Term Holding?
Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 - Here's Why
Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
Biogen Inc. (NASDAQ:BIIB) Q4 2025 Earnings Call Transcript
Ruth: Please stand by. Morning. My name is Ruth, and I will be your conference operator today.
Here's What Analysts Think About Biogen Inc. (BIIB)
Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8.
Hedge Fund Resource Center